Can Pharmacyclics Turn It Around?

Today, fool.com health-care analysts Brenton Flynn and David Williamson examine Pharmacyclics' September drop and look to explain the move. The company saw a huge run-up in August that raises the stakes for success. David cautions that a slip-up will send shares spiraling, as the company still doesn't have its potentially blockbuster drug in phase 3 trials at this time. 

When it comes to do-or-die businesses, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.

Brenton Flynn and Dave Williamson have no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (3) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 03, 2012, at 11:42 PM, malibusunsetter wrote:

    WHat on earth is this article about? Not in phase III - can the authors not read? They are near their 52 week high as of today. Ever heard of profit taking? Myeloma results to be presented at ASH? You think they will publish poor results?

  • Report this Comment On October 04, 2012, at 9:35 AM, malibusunsetter wrote:

    Three phase III trials for Ibrutinib.

  • Report this Comment On October 04, 2012, at 1:36 PM, NVR2LATE4 wrote:

    Did someone just hire a seeking alpha writer? I read through this story, the entire time thinking, Do the have the right ticker symbol?

Add your comment.

DocumentId: 2039390, ~/Articles/ArticleHandler.aspx, 4/16/2014 9:35:07 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement